1. Home
  2. ENFN vs ABVX Comparison

ENFN vs ABVX Comparison

Compare ENFN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENFN
  • ABVX
  • Stock Information
  • Founded
  • ENFN 1998
  • ABVX 2013
  • Country
  • ENFN United States
  • ABVX France
  • Employees
  • ENFN N/A
  • ABVX N/A
  • Industry
  • ENFN Computer Software: Prepackaged Software
  • ABVX
  • Sector
  • ENFN Technology
  • ABVX
  • Exchange
  • ENFN Nasdaq
  • ABVX Nasdaq
  • Market Cap
  • ENFN 826.8M
  • ABVX 722.3M
  • IPO Year
  • ENFN 2021
  • ABVX N/A
  • Fundamental
  • Price
  • ENFN $10.85
  • ABVX $7.80
  • Analyst Decision
  • ENFN Hold
  • ABVX Strong Buy
  • Analyst Count
  • ENFN 5
  • ABVX 6
  • Target Price
  • ENFN $9.80
  • ABVX $38.67
  • AVG Volume (30 Days)
  • ENFN 435.8K
  • ABVX 119.0K
  • Earning Date
  • ENFN 11-04-2024
  • ABVX 09-09-2024
  • Dividend Yield
  • ENFN N/A
  • ABVX N/A
  • EPS Growth
  • ENFN N/A
  • ABVX N/A
  • EPS
  • ENFN 0.03
  • ABVX N/A
  • Revenue
  • ENFN $195,159,000.00
  • ABVX $9,676,417.00
  • Revenue This Year
  • ENFN $18.88
  • ABVX $31.67
  • Revenue Next Year
  • ENFN $17.75
  • ABVX $1,189.66
  • P/E Ratio
  • ENFN $354.82
  • ABVX N/A
  • Revenue Growth
  • ENFN 15.78
  • ABVX 100.87
  • 52 Week Low
  • ENFN $7.52
  • ABVX $7.11
  • 52 Week High
  • ENFN $11.38
  • ABVX $17.02
  • Technical
  • Relative Strength Index (RSI)
  • ENFN 77.03
  • ABVX 38.81
  • Support Level
  • ENFN $10.43
  • ABVX $7.11
  • Resistance Level
  • ENFN $10.75
  • ABVX $8.18
  • Average True Range (ATR)
  • ENFN 0.28
  • ABVX 0.48
  • MACD
  • ENFN 0.07
  • ABVX -0.01
  • Stochastic Oscillator
  • ENFN 94.72
  • ABVX 36.13

About ENFN Enfusion Inc.

Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute an informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth. It generates maximum revenue from Americas, followed by Asia Pacific and Europe, Middle East, and Africa.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.

Share on Social Networks: